Search Results: Treatment + Prostate Cancer + Hormone Sensitive (1 results)
Treatment for Metastatic Castration-Sensitive Prostate Cancer and Inherited or Tumor Mutations in DNA Damage Repair Genes (Amplitude)
https://www.facingourrisk.org/research-clinical-trials/study/209/treatment-for-metastatic-castration-sensitive-prostate-cancer-and-inherited-or-tumor-mutations-in-dna-damage-repair-genes-amplitude
Treatment
Treatment for metastatic castration-sensitive prostate cancer and a tumor or inherited mutation in BRCA1, BRCA2, ATM, BRIP1, CHEK2, PALB2 or related gene
The goal of AMPLITUDE is to see if adding the PARP inhibitor niraparib to standard of care hormone therapy (Abiraterone Acetate, prednisone and androgen deprivation therapy (ADT) is safe and more effective than standard of care alone. The study is enrolling people who have metastatic castration-sensitive prostate cancer and have an inherited or tumor mutation in one of the following genes involved in DNA damage repair: BRCA2, BRCA1, BRIP1, CHEK2, FANCA, PALB2, RAD51B and RAD54L.
Additional Results on Clinicaltrials.gov Treatment + Prostate Cancer + Hormone Sensitive + adt
61 results
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
NCT ID: NCT04748042 (https://classic.clinicaltrials.gov/show/NCT04748042)
Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer
NCT ID: NCT04298983 (https://classic.clinicaltrials.gov/show/NCT04298983)
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
NCT ID: NCT05628363 (https://classic.clinicaltrials.gov/show/NCT05628363)
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
NCT ID: NCT05477823 (https://classic.clinicaltrials.gov/show/NCT05477823)
T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
NCT ID: NCT05361798 (https://classic.clinicaltrials.gov/show/NCT05361798)
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
NCT ID: NCT03543189 (https://classic.clinicaltrials.gov/show/NCT03543189)
EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
NCT ID: NCT04465500 (https://classic.clinicaltrials.gov/show/NCT04465500)
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
NCT ID: NCT04947254 (https://classic.clinicaltrials.gov/show/NCT04947254)
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
NCT ID: NCT05100472 (https://classic.clinicaltrials.gov/show/NCT05100472)
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
NCT ID: NCT05169970 (https://classic.clinicaltrials.gov/show/NCT05169970)
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
NCT ID: NCT05676463 (https://classic.clinicaltrials.gov/show/NCT05676463)
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
NCT ID: NCT03361735 (https://classic.clinicaltrials.gov/show/NCT03361735)
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
NCT ID: NCT04349501 (https://classic.clinicaltrials.gov/show/NCT04349501)
CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
NCT ID: NCT01985828 (https://classic.clinicaltrials.gov/show/NCT01985828)
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
NCT ID: NCT04402151 (https://classic.clinicaltrials.gov/show/NCT04402151)
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
NCT ID: NCT04943536 (https://classic.clinicaltrials.gov/show/NCT04943536)
BEACON: HDR Brachytherapy, EBRT and STAD for the Treatment of Local and Pelvic Recurrence of Prostate Cancer After Radiation Therapy
NCT ID: NCT03553602 (https://classic.clinicaltrials.gov/show/NCT03553602)
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
NCT ID: NCT05155046 (https://classic.clinicaltrials.gov/show/NCT05155046)
Pembro With Radiation With or Without Olaparib
NCT ID: NCT05568550 (https://classic.clinicaltrials.gov/show/NCT05568550)
RElugolix VErsus LeUprolide Cardiac Trial
NCT ID: NCT05320406 (https://classic.clinicaltrials.gov/show/NCT05320406)
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
NCT ID: NCT05915442 (https://classic.clinicaltrials.gov/show/NCT05915442)
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
NCT ID: NCT03624660 (https://classic.clinicaltrials.gov/show/NCT03624660)
INTREPId (INTermediate Risk Erection PreservatIon Trial)
NCT ID: NCT04025372 (https://classic.clinicaltrials.gov/show/NCT04025372)
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
NCT ID: NCT04019964 (https://classic.clinicaltrials.gov/show/NCT04019964)
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
NCT ID: NCT03456843 (https://classic.clinicaltrials.gov/show/NCT03456843)
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer
NCT ID: NCT05053152 (https://classic.clinicaltrials.gov/show/NCT05053152)
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
NCT ID: NCT03951831 (https://classic.clinicaltrials.gov/show/NCT03951831)
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
NCT ID: NCT04734730 (https://classic.clinicaltrials.gov/show/NCT04734730)
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
NCT ID: NCT04725903 (https://classic.clinicaltrials.gov/show/NCT04725903)
Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
NCT ID: NCT04705038 (https://classic.clinicaltrials.gov/show/NCT04705038)
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
NCT ID: NCT04633252 (https://classic.clinicaltrials.gov/show/NCT04633252)
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
NCT ID: NCT03413995 (https://classic.clinicaltrials.gov/show/NCT03413995)
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
NCT ID: NCT05617885 (https://classic.clinicaltrials.gov/show/NCT05617885)
A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones
NCT ID: NCT05133440 (https://classic.clinicaltrials.gov/show/NCT05133440)
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
NCT ID: NCT05050084 (https://classic.clinicaltrials.gov/show/NCT05050084)
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer
NCT ID: NCT04787744 (https://classic.clinicaltrials.gov/show/NCT04787744)
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT ID: NCT04704505 (https://classic.clinicaltrials.gov/show/NCT04704505)
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
NCT ID: NCT04126070 (https://classic.clinicaltrials.gov/show/NCT04126070)
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT ID: NCT04513717 (https://classic.clinicaltrials.gov/show/NCT04513717)
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
NCT ID: NCT04116775 (https://classic.clinicaltrials.gov/show/NCT04116775)
Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer
NCT ID: NCT02040610 (https://classic.clinicaltrials.gov/show/NCT02040610)
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
NCT ID: NCT03436654 (https://classic.clinicaltrials.gov/show/NCT03436654)
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT ID: NCT04363164 (https://classic.clinicaltrials.gov/show/NCT04363164)
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
NCT ID: NCT05496959 (https://classic.clinicaltrials.gov/show/NCT05496959)
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
NCT ID: NCT05169684 (https://classic.clinicaltrials.gov/show/NCT05169684)
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
NCT ID: NCT03796767 (https://classic.clinicaltrials.gov/show/NCT03796767)
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT ID: NCT04493853 (https://classic.clinicaltrials.gov/show/NCT04493853)
Study of PCUR-101 in Combination With ADT in Patients With mCRPC
NCT ID: NCT04677855 (https://classic.clinicaltrials.gov/show/NCT04677855)
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
NCT ID: NCT03934840 (https://classic.clinicaltrials.gov/show/NCT03934840)
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT ID: NCT04423211 (https://classic.clinicaltrials.gov/show/NCT04423211)
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT04666129 (https://classic.clinicaltrials.gov/show/NCT04666129)
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
NCT ID: NCT05617040 (https://classic.clinicaltrials.gov/show/NCT05617040)
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT ID: NCT05348577 (https://classic.clinicaltrials.gov/show/NCT05348577)
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
NCT ID: NCT04175431 (https://classic.clinicaltrials.gov/show/NCT04175431)
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
NCT ID: NCT05605964 (https://classic.clinicaltrials.gov/show/NCT05605964)
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
NCT ID: NCT04253483 (https://classic.clinicaltrials.gov/show/NCT04253483)
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
NCT ID: NCT04288687 (https://classic.clinicaltrials.gov/show/NCT04288687)
Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer
NCT ID: NCT04421222 (https://classic.clinicaltrials.gov/show/NCT04421222)
Serial MRI Scans During Radiation Therapy
NCT ID: NCT04188535 (https://classic.clinicaltrials.gov/show/NCT04188535)
Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
NCT ID: NCT03637543 (https://classic.clinicaltrials.gov/show/NCT03637543)
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations
NCT ID: NCT05498272 (https://classic.clinicaltrials.gov/show/NCT05498272)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.